Abstract
EPO's biosimilars in oncology. After a reminder on general conditions for prescribing EPOs and international recommendations, the more specific prescription of biosimilars, their interchangeability, guidelines, traceability, are considered.
Cite
CITATION STYLE
APA
Chouaïd, C. (2012). The oncologist’s point of view. In Biosimilars: A New Generation of Biologics (pp. 61–70). Springer-Verlag France. https://doi.org/10.1007/978-2-8178-0336-4_6
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free